Journal of Dementia
Open Access

Huntington’s disease; Neurodegeneration; CAG repeats; Mutant huntingtin; Clinical manifestations; Therapeutic approaches

Introduction

Huntington’s disease (HD) is a devastating neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric disturbances [1]. First described by George Huntington in 1872, HD is caused by an expansion of CAG repeats in the huntingtin gene (HTT), leading to the production of mutant huntingtin protein (mHTT). The accumulation of mHTT in neurons results in cellular dysfunction and eventual neuronal death, particularly in the striatum and cortex. The clinical manifestations of HD typically manifest in mid-adulthood, although juvenile-onset cases can occur, presenting with earlier onset and more rapid disease progression. Despite decades of research, there is currently no cure for HD, and available treatments only provide symptomatic relief. This review aims to provide a comprehensive overview of HD, including its pathogenesis, clinical manifestations, and therapeutic approaches [2].

Background of huntington’s disease:

This subsection provides a brief historical overview of Huntington’s disease, including its initial discovery by George Huntington in 1872 and subsequent advancements in understanding the disease’s etiology and clinical manifestations.

Genetic Basis of huntington’s disease:

Here, the genetic underpinnings of Huntington’s disease are elucidated, focusing on the expansion of CAG repeats in the huntingtin gene and its association with disease onset and progression [3]. The role of genetic testing and counseling in HD diagnosis and management is also discussed.

Clinical significance of huntington’s disease:

This section highlights the profound impact of Huntington’s disease on affected individuals and their families, emphasizing the progressive nature of the disease and its multifaceted clinical manifestations, including motor, cognitive, and psychiatric symptoms.

Scope of the review:

The scope of the review is outlined, delineating the objectives and structure of the subsequent sections. This subsection provides a roadmap for the reader, guiding them through the comprehensive examination of HD pathogenesis, clinical manifestations, therapeutic approaches, and future directions in research and treatment development [4].

Importance of understanding huntington’s disease:

Finally, the significance of advancing our understanding of Huntington’s disease is underscored, emphasizing the urgent need for disease-modifying therapies and ultimately a cure. The potential impact of innovative research and collaborative efforts in improving outcomes for individuals affected by HD is discussed, setting the stage for the subsequent sections of the review [5].

Pathogenesis of huntington’s disease

HD is primarily caused by an expansion of CAG repeats in the HTT gene, located on chromosome 4. Normal individuals typically have 10 to 35 CAG repeats in the HTT gene, whereas individuals with HD have more than 40 repeats, with longer repeats associated with earlier disease onset and more severe symptoms [6]. The expanded CAG repeats lead to the production of mHTT, a misfolded protein that forms aggregates and exerts toxic effects on neurons. The precise mechanisms underlying mHTT toxicity are complex and multifaceted, involving disruption of cellular processes such as transcriptional dysregulation, mitochondrial dysfunction, excitotoxicity, and impaired protein degradation pathways. These pathological processes ultimately result in neuronal dysfunction and cell death, particularly affecting the striatal medium spiny neurons and cortical pyramidal neurons.

Clinical manifestations of huntington’s disease

The clinical presentation of HD is characterized by a triad of motor, cognitive, and psychiatric symptoms. Motor symptoms typically manifest as chorea, a hyperkinetic movement disorder characterized by involuntary, jerky movements that are often random and unpredictable. Chorea can progress to more pronounced motor impairments, including dystonia, bradykinesia, and rigidity [7]. Cognitive symptoms in HD commonly include impairments in executive function, attention, and visuospatial skills, leading to difficulties in planning, organizing, and executing tasks. Psychiatric symptoms, such as depression, anxiety, irritability, and apathy, are also common in HD and can significantly impact quality of life (Table 1).

Table 1: Clinical Manifestations of Huntington's Disease.

Juvenile-onset huntington’s disease

While the majority of individuals with HD develop symptoms in mid-adulthood, juvenile-onset HD can occur when symptoms manifest before the age of 20. Juvenile-onset HD is characterized by earlier onset, more rapid disease progression, and distinct clinical features compared to adult-onset HD. Common manifestations of juvenile-onset HD include rigidity, bradykinesia, and seizures, with cognitive decline often preceding motor symptoms. Genetic testing and counseling are essential for individuals with a family history of HD, particularly in cases of juvenile-onset disease.

Therapeutic approaches for huntington’s disease

Currently, there is no cure for HD, and available treatments aim to alleviate symptoms and improve quality of life. Pharmacological interventions for HD include dopamine-depleting agents such as tetrabenazine and neuroprotective compounds such as coenzyme Q10 and creatine. Non-pharmacological approaches, such as physical therapy, speech therapy, and occupational therapy, can also help manage motor and cognitive symptoms. Emerging therapeutic strategies for HD include gene silencing techniques such as antisense oligonucleotides and RNA interference, which aim to reduce the expression of mHTT [8]. Stem cell therapy holds promise for replacing damaged neurons and restoring neural function in HD-affected brain regions. However, further research is needed to optimize these therapeutic approaches and assess their long-term efficacy and safety (Table 2).

Table 2: Therapeutic Approaches for Huntington's Disease.

Results and Discussion

Pathogenesis of huntington’s disease:

The primary causative factor of Huntington’s disease (HD) is the expansion of CAG repeats in the huntingtin gene (HTT), leading to the production of mutant huntingtin protein (mHTT). This abnormal protein undergoes misfolding and aggregation, resulting in neuronal dysfunction and eventual cell death. The pathological mechanisms underlying HD are complex and multifaceted, involving disruptions in cellular processes such as transcriptional dysregulation, mitochondrial dysfunction, excitotoxicity, and impaired protein degradation pathways. These pathological changes predominantly affect the striatum and cortex, leading to the characteristic motor, cognitive, and psychiatric symptoms observed in HD [9].

Clinical manifestations of huntington’s disease:

HD is clinically characterized by a triad of motor, cognitive, and psychiatric symptoms. Motor symptoms, such as chorea, dystonia,bradykinesia, and rigidity, are prominent features of the disease and significantly impact functional abilities. Cognitive impairments in HD typically manifest as deficits in executive function, attention, and visuospatial skills, leading to difficulties in planning, organizing, and executing tasks. Psychiatric symptoms, including depression, anxiety, irritability, and apathy, further exacerbate the burden of the disease and impair quality of life for affected individuals.

Juvenile-onset huntington’s disease:

While most individuals with HD develop symptoms in midadulthood, juvenile-onset HD can occur when symptoms manifest before the age of 20. Juvenile-onset HD is characterized by earlier onset, more rapid disease progression, and distinct clinical features compared to adult-onset HD. Common manifestations of juvenileonset HD include rigidity, bradykinesia, and seizures, with cognitive decline often preceding motor symptoms. Early identification and intervention are critical in managing juvenile-onset HD and improving outcomes for affected individuals.

Therapeutic approaches for huntington’s disease:

Currently, there is no cure for HD, and available treatments primarily aim to alleviate symptoms and improve quality of life. Pharmacological interventions, such as dopamine-depleting agents and neuroprotective compounds, can help manage motor and psychiatric symptoms [10]. Non-pharmacological approaches, including physical therapy, speech therapy, and occupational therapy, are also valuable in addressing functional impairments associated with HD. Emerging therapeutic strategies, such as gene silencing techniques and stem cell therapy, offer promising avenues for disease modification and potential disease reversal. However, further research is needed to optimize these treatments and assess their long-term efficacy and safety.

Conclusion

Huntington’s disease is a devastating neurodegenerative disorder characterized by progressive motor dysfunction, cognitive decline, and psychiatric disturbances. While significant progress has been made in understanding the pathogenesis of HD and developing symptomatic treatments, there is still an urgent need for disease-modifying therapies and ultimately a cure. Emerging therapeutic strategies such as gene silencing and stem cell therapy offer promising avenues for disease modification and potential disease reversal. However, further research is needed to translate these experimental approaches into clinically effective treatments for HD. Collaborative efforts involving researchers, clinicians, patients, and advocacy groups are essential to advance our understanding of HD and develop effective therapies to improve the lives of affected individuals and their families.

Acknowledgment

None

Conflict of Interest

None

1. Urzi F, Pokorny B, Buzan E (2020)Pilot Study on Genetic Associations With Age-Related Sarcopenia. Front Genet 11: 615238.

Indexed at, Google Scholar, Crossref

2. Starkweather AR, Witek-Janusek L, Nockels RP, Peterson J, Mathews HL (2008)The Multiple Benefits of Minimally Invasive Spinal Surgery: Results Comparing Transforaminal Lumbar Interbody Fusion and Posterior Lumbar Fusion. J Neurosci Nurs 40: 32–39.

Indexed at, Google Scholar, Crossref

3. Bauer JM, Verlaan S, Bautmans I, Brandt K, Donini LM, et al. (2015)Effects of a vitamin D and leucine-enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: a randomized, double-blind, placebo-controlled trial.J Am Med Dir Assoc 16: 740–747.

Indexed at, Google Scholar, Crossref

4. Inose H, Yamada T, Hirai T, Yoshii T, Abe Y, et al.( 2018)The impact of sarcopenia on the results of lumbar spinal surgery. Osteoporosis and Sarcopenia 4: 33–36.

Indexed at, Google Scholar, Crossref

5. DigheDeo D, Shah A (1998)Electroconvulsive Therapy in Patients with Long Bone Fractures.J ECT 14: 115–119.

Indexed at, Google Scholar

6. Takahashi S, Mizukami K, Yasuno F, Asada T (2009)Depression associated with dementia with Lewy bodies (DLB) and the effect of somatotherapy.Psychogeriatrics 9: 56–61.

Indexed at, Google Scholar, Crossref

7. Bellgrove MA, Chambers CD, Vance A, Hall N, Karamitsios M, et al. (2006)Lateralized deficit of response inhibition in early-onset schizophrenia. Psychol Med 36: 495-505.

Indexed at, Google Scholar, Crossref

8. Carter CS, Barch DM (2007)Cognitive neuroscience-based approaches to measuring and improving treatment effects on cognition in schizophrenia: the CNTRICS initiative. Schizophr Bull 33: 1131-1137.

Indexed at, Google Scholar, Crossref

9. Gupta S, Fenves AZ, Hootkins R (2016)The Role of RRT in Hyperammonemic Patients. Clin J Am Soc Nephrol 11: 1872-1878.

Indexed at, Google Scholar, Crossref

10. Komamura K, Fukui M, Iwasaku T, Hirorani S, Masuyama T, et al (2014)Takotsubo cardiomyopathy: pathophysiology, diagnosis, and treatment. World J Cardiol 6: 602-609.

Indexed at, Google Scholar, CrossRef